6533b82cfe1ef96bd128f5d9
RESEARCH PRODUCT
Contemporary Management of Struvite Stones Using Combined Endourologic and Medical Treatment: Predictors of Unfavorable Clinical Outcome
Michael E. LipkinGlenn M. PremingerRamy F. YoussefAndreas NeisiusAndreas NeisiusNicholas J. KuntzJonathan HannaMichael N. FerrandinoMuhammad W. Iqbalsubject
AdultMalemedicine.medical_specialtyStruviteUrologymedicine.medical_treatment030232 urology & nephrologyComorbidityHydroxamic AcidsKidney CalculiYoung Adult03 medical and health scienceschemistry.chemical_compoundPostoperative Complications0302 clinical medicineRecurrencePotassium CitratemedicineHumansUniversity medicalEnzyme InhibitorsDiureticsPercutaneous nephrolithotomyAgedNephrostomy PercutaneousRetrospective StudiesAged 80 and overRetrospective reviewMedical treatmentbusiness.industryChlorthalidoneRetrospective cohort studyMiddle Agedmedicine.diseaseComorbidityAnti-Bacterial AgentsSurgerySodium BicarbonateTreatment OutcomechemistryStruvite030220 oncology & carcinogenesisNephrostomyFemaleCalcium Citratebusinessdescription
Struvite stones have been associated with significant morbidity and mortality, yet there has not been a report on the medical management of struvite stones in almost 20 years. We report on the contemporary outcomes of the surgical and medical management of struvite stones in a contemporary series.A retrospective review of patients who were treated with percutaneous nephrolithotomy (PCNL) for struvite stones at Duke University Medical Center between January 2005 and September 2012 identified a total of 75 patients. Of these, 43 patients had adequate follow-up and were included in this analysis. Stone activity, defined as either stone recurrence or stone-related events, and predictors of activity were evaluated after combined surgical and medical treatment.The study included 43 patients with either pure (35%) or mixed (65%) struvite stones with a median age of 55±15 years (range 21-89 years). The stone-free rate after PCNL was 42%. Stone recurrence occurred in 23% of patients. Postoperatively, 30% of patients had a stone-related event, while 60% of residual stones remained stable with no growth after a median follow-up of 22 months (range 6-67 mos). Kidney function remained stable during follow-up. Independent predictors of stone activity included the presence of residual stones0.4 cm(2), preoperative large stone burden (10 cm(2)), and the presence of medical comorbidities (P0.05).Struvite stones can be managed safely with PCNL followed by medical therapy. The majority of patients with residual fragments demonstrated no evidence of stone growth on medical therapy. With careful follow-up and medical management, kidney function can be maintained and stone morbidity can be minimized. Initial large stone burden, residual stones after surgery, and associated medical comorbidities may have deleterious effect on stone recurrence or residual stone-related events.
year | journal | country | edition | language |
---|---|---|---|---|
2016-07-01 | Journal of Endourology |